New Therapies in Hepatitis C Virus and Chronic Liver Disease: Antifibrotics

Clinics in Liver Disease

Volumn 10, Issue 4, 2006, Pages 881-900

  Rockey, Don C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIFIBROTIC AGENT; CHOLINE DERIVATIVE; COLCHICINE; GAMMA INTERFERON; HALOFUGINONE; INTERLEUKIN 10; MALOTILATE; METHOTREXATE; OXANDROLONE; PENICILLAMINE; PIRFENIDONE; POLYENE PHOSPHATIDYLCHOLINE; PROPYLTHIOURACIL; ROSIGLITAZONE; S ADENOSYLMETHIONINE; SCLEROPROTEIN; SILYMARIN; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; URSODEOXYCHOLIC ACID;

BILIARY CIRRHOSIS; BLOOD FLOW; CELL ACTIVATION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; EFFECTOR CELL; EXTRACELLULAR MATRIX; FIBROGENESIS; HEPATITIS C; HUMAN; IMMUNE SYSTEM; LIVER DYSFUNCTION; LIVER FIBROSIS; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; REVIEW; STELLATE CELL;

COLCHICINE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; LIVER CIRRHOSIS; PHOSPHATIDYLCHOLINES; SILYMARIN; URSODEOXYCHOLIC ACID;

EID: 33845316462     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2006.08.019     Document Type: Review

References (133)

1. Rockey DC, Friedman SL. Hepatic fibrosis. In: Boyer TD, Wright TL, Manns MP, editors. Zakim and Boyer's hepatology: a textbook of liver disease. 5th edition. Philadelphia: Saunders; 2006.
2. Kim W.R., Brown Jr. R.S., Terrault N.A., et al. Burden of liver disease in the United States: summary of a workshop. Hepatology 36 (2002) 227
3. El-Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36 (2002) S74
4. Davis G.L., Albright J.E., Cook S.F., et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9 (2003) 331
5. Bruix J., Boix L., Sala M., et al. Focus on hepatocellular cancer. Cancer Cell 5 (2004) 215
6. Poynard T., Ratziu V., Charlotte F., et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34 (2001) 730
7. Martin P. Wound healing: aiming for perfect skin regeneration. Science 276 (1997) 75
8. Schaffer C.J., and Nanney L.B. Cell biology of wound healing. Int Rev Cytol 169 (1996) 151
9. Holstege A., Bedossa P., Poynard T., et al. Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: localization and association with progression of liver fibrosis. Hepatology 19 (1994) 367 [erratum: Hepatology 1994;20:1664]
10. Lee K.S., Buck M., Houglum K., et al. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 96 (1995) 2461
11. Svegliati Baroni G., D'Ambrosio L., Ferretti G., et al. Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology 27 (1998) 720
12. Choy-Smith C, Sempkowski G, Rockey DC. Increased hepatic fibrosis in very young mice is associated with induction of liver natural killer cells. Hepatology 2001;34:394A.
13. Novobrantseva T.I., Majeau G.R., Amatucci A., et al. Attenuated liver fibrosis in the absence of B cells. J Clin Invest 115 (2005) 3072
14. Safadi R., Ohta M., Alvarez C.E., et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 127 (2004) 870
15. Friedman S.L., Roll F.J., Boyles J., et al. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A 82 (1985) 8681
16. Johnson R.J., Iida H., Alpers C.E., et al. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis: alpha-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 87 (1991) 847
17. Kent G., Gay S., Inouye T., et al. Vitamin A-containing lipocytes and formation of type III collagen in liver injury. Proc Natl Acad Sci U S A 73 (1976) 3719
18. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303
19. Rojkind M., and Martinez-Palomo A. Increase in type I and type III collagens in human alcoholic liver cirrhosis. Proc Natl Acad Sci U S A 73 (1976) 539
20. Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 10 (1990) 1
21. Gallai M., Kovalszky I., Knittel T., et al. Expression of extracellular matrix proteoglycans perlecan and decorin in carbon-tetrachloride-injured rat liver and in isolated liver cells. Am J Pathol 148 (1996) 1463
22. Meyer D.H., Krull N., Dreher K.L., et al. Biglycan and decorin gene expression in normal and fibrotic rat liver: cellular localization and regulatory factors. Hepatology 16 (1992) 204
23. Jezequel A.M., Ballardini G., Mancini R., et al. Modulation of extracellular matrix components during dimethylnitrosamine-induced cirrhosis. J Hepatol 11 (1990) 206
24. Maher J.J., and McGuire R.F. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 86 (1990) 1641
25. Jarnagin W.R., Rockey D.C., Koteliansky V.E., et al. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 127 (1994) 2037
26. Van Eyken P., Geerts A., De Bleser P., et al. Localization and cellular source of the extracellular matrix protein tenascin in normal and fibrotic rat liver. Hepatology 15 (1992) 909
27. Wake K. Perisinusoidal stellate cells (fat-storing cells, interstitial cells, lipocytes), their related structure in and around the liver sinusoids, and vitamin A-storing cells in extrahepatic organs. Int Rev Cytol 66 (1980) 303
28. Gressner A.M., Weiskirchen R., Breitkopf K., et al. Roles of TGF-beta in hepatic fibrosis. Front Biosci 7 (2002) D793
29. Friedman S.L., and Arthur M.J. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium: direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest 84 (1989) 1780
30. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 25 (1997) 2
31. Rockey D.C., Housset C.N., and Friedman S.L. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest 92 (1993) 1795
32. Marra F. Chemokines in liver inflammation and fibrosis. Front Biosci 7 (2002) d1899
33. Marra F., Valente A.J., Pinzani M., et al. Cultured human liver fat-storing cells produce monocyte chemotactic protein-1: regulation by proinflammatory cytokines. J Clin Invest 92 (1993) 1674
34. Pinzani M., Abboud H.E., Gesualdo L., et al. Regulation of macrophage colony-stimulating factor in liver fat-storing cells by peptide growth factors. Am J Physiol 262 (1992) C876
35. Pinzani M., and Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 21 (2001) 397
36. Arthur M.J., Friedman S.L., Roll F.J., et al. Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type IV) collagen. J Clin Invest 84 (1989) 1076
37. Iredale J.P. Stellate cell behavior during resolution of liver injury. Semin Liver Dis 21 (2001) 427
38. Iredale J.P., Murphy G., Hembry R.M., et al. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1: implications for regulation of matrix degradation in liver. J Clin Invest 90 (1992) 282
39. Canbay A., Taimr P., Torok N., et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 83 (2003) 655
40. Bataller R., Paik Y.H., Lindquist J.N., et al. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126 (2004) 529
41. Mazzocca A., Sciammetta S.C., Carloni V., et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem 280 (2005) 11329
42. Rockey D.C., Boyles J.K., Gabbiani G., et al. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 24 (1992) 193
43. Rockey D.C. Vascular mediators in the injured liver. Hepatology 37 (2003) 4
44. Sims D.E. Recent advances in pericyte biology: implications for health and disease. Can J Cardiol 7 (1991) 431
45. Bauer M., Paquette N.C., Zhang J.X., et al. Chronic ethanol consumption increases hepatic sinusoidal contractile response to endothelin-1 in the rat. Hepatology 22 (1995) 1565
46. Rockey D.C., and Weisiger R.A. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 24 (1996) 233
47. Irle C., Kocher O., and Gabbiani G. Contractility of myofibroblasts during experimental liver cirrhosis. J Submicrosc Cytol 12 (1980) 209
48. Bissell D.M., Wang S.S., Jarnagin W.R., et al. Cell-specific expression of transforming growth factor-beta in rat liver: evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 96 (1995) 447
49. Marra F., Choudhury G.G., Pinzani M., et al. Regulation of platelet-derived growth factor secretion and gene expression in human liver fat-storing cells. Gastroenterology 107 (1994) 1110
50. Paradis V., Dargere D., Vidaud M., et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 30 (1999) 968
51. Shao R., Yan W., and Rockey D.C. Regulation of endothelin-1 synthesis by endothelin-converting enzyme-1 during wound healing. J Biol Chem 274 (1999) 3228
52. Bataller R., Gines P., Nicolas J.M., et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118 (2000) 1149
53. Iredale J.P., Benyon R.C., Pickering J., et al. Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 102 (1998) 538
54. Arthur M.J., Stanley A., Iredale J.P., et al. Secretion of 72 kDa type IV collagenase/gelatinase by cultured human lipocytes: analysis of gene expression, protein synthesis and proteinase activity. Biochem J 287 (1992) 701
55. Takahara T., Furui K., Funaki J., et al. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 21 (1995) 787
56. Arthur M.J., and Fibrogenesis I.I. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 279 (2000) G245
57. Herbst H., Wege T., Milani S., et al. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol 150 (1997) 1647
58. Yoshiji H., Kuriyama S., Yoshii J., et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36 (2002) 850
59. Preaux A.M., Mallat A., Van Nhieu J.T., et al. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 30 (1999) 944
60. Olaso E., Ikeda K., Eng F.J., et al. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J Clin Invest 108 (2001) 1369
61. Han Y.P., Zhou L., Wang J., et al. Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 279 (2004) 4820
62. Burridge K., and Chrzanowska-Wodnicka M. Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol 12 (1996) 463
63. Racine-Samson L., Rockey D.C., and Bissell D.M. The role of alpha1beta1 integrin in wound contraction: a quantitative analysis of liver myofibroblasts in vivo and in primary culture. J Biol Chem 272 (1997) 30911
64. Zhou X., Murphy F.R., Gehdu N., et al. Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem 279 (2004) 23996
65. Baroni G.S., D'Ambrosio L., Curto P., et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 23 (1996) 1189
66. Rockey D.C., and Chung J.J. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Investig Med 42 (1994) 660
67. Radaeva S., Sun R., Jaruga B., et al. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130 (2006) 435
68. Shi Z., Wakil A.E., and Rockey D.C. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A 94 (1997) 10663
69. Regev A., Berho M., Jeffers L.J., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 (2002) 2614
70. Rockey D.C., and Bissell D.M. Noninvasive measures of liver fibrosis. Hepatology 43 (2006) S113
71. Dufour J.F., DeLellis R., and Kaplan M.M. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci 43 (1998) 2573
72. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808
73. Dufour J.F., DeLellis R., and Kaplan M.M. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 127 (1997) 981
74. Ramond M.J., Poynard T., Rueff B., et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 326 (1992) 507
75. Perez-Tamayo R. Cirrhosis of the liver: a reversible disease?. Pathol Annu 14 (1979) 183
76. Hammel P., Couvelard A., O'Toole D., et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 344 (2001) 418
77. Rodriguez L., Cerbon-Ambriz J., and Munoz M.L. Effects of colchicine and colchiceine in a biochemical model of liver injury and fibrosis. Arch Med Res 29 (1998) 109
78. Kaplan M.M., Alling D.W., Zimmerman H.J., et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 315 (1986) 1448
79. Kershenobich D., Vargas F., Garcia-Tsao G., et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 318 (1988) 1709
80. Morgan TR WD, Nemchausky B, Schiff ER, et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 2005;128:882.
81. Rambaldi A., and Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis. Liver 21 (2001) 129
82. Lieber C.S., Weiss D.G., Groszmann R., et al. II. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in Alcoholic Liver Disease. Alcohol Clin Exp Res 27 (2003) 1765
83. Thompson K., Maltby J., Fallowfield J., et al. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. [see comments]. Hepatology 28 (1998) 1597
84. Nelson D.R., Tu Z., Soldevila-Pico C., et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 38 (2003) 859
85. Rockey D.C., Maher J.J., Jarnagin W.R., et al. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Hepatology 16 (1992) 776
86. Toyonaga T., Hino O., Sugai S., et al. Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc Natl Acad Sci U S A 91 (1994) 614
87. Muir A.J., Sylvestre P.B., and Rockey D.C. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepat 13 (2006) 322
88. Boigk G., Stroedter L., Herbst H., et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26 (1997) 643
89. Jia J.D., Bauer M., Cho J.J., et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 35 (2001) 392
90. Lieber C.S., Leo M.A., Cao Q., et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 37 (2003) 336
91. Ferenci P., Dragosics B., Dittrich H., et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9 (1989) 105
92. Pares A., Planas R., Torres M., et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. [see comments]. J Hepatol 28 (1998) 615
93. Nava-Ocampo A.A., Suster S., and Muriel P. Effect of colchiceine and ursodeoxycholic acid on hepatocyte and erythrocyte membranes and liver histology in experimentally induced carbon tetrachloride cirrhosis in rats. Eur J Clin Invest 27 (1997) 77
94. Combes B., Carithers Jr. R.L., Maddrey W.C., et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22 (1995) 759
95. Degott C., Zafrani E.S., Callard P., et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 29 (1999) 1007
96. Goulis J., Leandro G., and Burroughs A.K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354 (1999) 1053
97. Jacquemin E., Hermans D., Myara A., et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 25 (1997) 519
98. Lindblad A., Glaumann H., and Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 27 (1998) 166
99. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39 (2004) 770
100. Poupon R.E., Bonnand A.M., Chretien Y., et al. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 29 (1999) 1668
101. Poupon R.E., Lindor K.D., Pares A., et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 39 (2003) 12
102. Stiehl A. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Ann Med 26 (1994) 345
103. Combes B., Luketic V.A., Peters M.G., et al. Prolonged follow-up of patients in the US multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 99 (2004) 264
104. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 (2003) 1008
105. Brown K.E., Poulos J.E., Li L., et al. Effect of vitamin E supplementation on hepatic fibrogenesis in chronic dietary iron overload. Am J Physiol 272 (1997) G116
106. Hasegawa T., Yoneda M., Nakamura K., et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15 (2001) 1667
107. Houglum K., Venkataramani A., Lyche K., et al. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 113 (1997) 1069
108. Mezey E., Potter J., Rennie-Tankersley L., et al. A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology 38 (2003) 264A
109. Stewart S., Prince M., Bassendine M., et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 36 (2002) 16
110. Anonymous. The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis: a European multicentre study group. J Hepatol 17 (1993) 227
111. Schaff Z., Lapis K., Szende B., et al. The effect of D-penicillamine on CCl4-induced experimental liver cirrhosis. Exp Pathol 43 (1991) 111
112. Bodenheimer Jr. H.C., Schaffner F., Sternlieb I., et al. A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 5 (1985) 1139
113. Dickson E.R., Fleming T.R., Wiesner R.H., et al. Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med 312 (1985) 1011
114. Aithal G.P., Haugk B., Das S., et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?. Aliment Pharmacol Ther 19 (2004) 391
115. Kaplan M.M., DeLellis R.A., and Wolfe H.J. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 126 (1997) 682
116. Combes B., Emerson S.S., Flye N.L., et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 42 (2005) 1184
117. Lu S.C., Tsukamoto H., and Mato J.M. Role of abnormal methionine metabolism in alcoholic liver injury. Alcohol 27 (2002) 155
118. Mato J.M., Camara J., Fernandez de Paz J., et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 30 (1999) 1081
119. Rambaldi A., and Gluud C. Meta-analysis of propylthiouracil for alcoholic liver disease: a Cochrane Hepato-Biliary Group Review. Liver 21 (2001) 398
120. Rambaldi A., Iaquinto G., and Gluud C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. Am J Gastroenterol 97 (2002) 1674
121. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 1637
122. Menon K.V., Stadheim L., Kamath P.S., et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 99 (2004) 255
123. Spahr L., Rubbia-Brandt L., Frossard J.L., et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 37 (2002) 448
124. Tilg H., Jalan R., Kaser A., et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 38 (2003) 419
125. Rockey D.C. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 3 (2005) 95
126. Isaka Y., Brees D.K., Ikegaya K., et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 2 (1996) 418
127. George J., Roulot D., Koteliansky V.E., et al. In vivo inhibition of rat stellate cell activation by soluble TGF beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 96 (1999) 12719
128. Yata Y., Gotwals P., Koteliansky V., et al. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 35 (2002) 1022
129. Di Sario A., Bendia E., Svegliati Baroni G., et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 37 (2002) 584
130. Marra F., Efsen E., Romanelli R.G., et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119 (2000) 466
131. Miyahara T., Schrum L., Rippe R., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275 (2000) 35715
132. Yang L., Chan C.C., Kwon O.S., et al. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 291 (2006) G902
133. Bruck R., Genina O., Aeed H., et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 33 (2001) 379